Brian Agan, MD

Brian K Agan, MD

Name: Brian K Agan, MD

USU Department of Primary Appointment: 
Preventive Medicine and Biostatistics
Title: 
Deputy Science Director; HIV Research Area Director
Faculty Rank: 
Associate Professor
Location: 
Uniformed Services University of the Health Sciences, Bethesda, MD

Research Interests:
HIV outcomes: pathogenesis, management, and prevention
HIV antiretroviral therapy; HIV associated neurocognitive disorders

Office Phone: 
(301) 816-8446

Education

BA - Chemistry; Colorado College, Colorado Springs, CO
MD - University of Colorado School of Medicine, Denver, CO
Internship & Residency - Internal Medicine; Wilford Hall USAF Medical Center, San Antonio, TX
Fellowship - Infectious Diseases; Wilford Hall USAF Medical Center, San Antonio, TX

Biography

Dr. Agan currently serves as the Deputy Science Director and HIV Research Director in the Infectious Disease Clinical Research Program at the Uniformed Services University through the Henry M. Jackson Foundation for the Advancement of Military Medicine. He has been part of military HIV clinical care and research for 20 years, serving roles including US Air Force HIV Unit Director and US Military HIV Natural History Study (NHS) site and lead PI. Major research interests include understanding outcomes of HIV infection and its treatment at the individual and population levels, with a focus on serious non-AIDS outcomes including diagnosis and prevention of HIV associated neurocognitive disorders (HAND).

Representative publications, projects, and/or deployments

  • CURRENT RESEARCH:
  • 2001-present: Principal Investigator 2008-present, Site Co-PI 2005-08, Site PI 2003-05, Site AI 2001-03: A Retrospective and Prospective Observational Study of the Natural History of HIV Infection in Active Duty U.S. Military Personnel and Department of Defense Beneficiaries, IDCRP-000. [multiple USU students have been involved (Med and MPH); many IM/ID residents/fellows have also been involved]
  • 2008-present: DoD Coordinating Principal Investigator (4 sites): Strategic Timing of AntiRetroviral Treatment (START, an International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) study - protocol co-Chairs: Abdel Babiker, Sean Emery, Fred Gordin, Jens Lundgren), IDCRP-038.
  • 2014-present: Principal Investigator: Evaluation of HIV-associated Neurocognitive Disorders (HAND) Among Military HIV-infected Subjects, IDCRP-078. [seeking student/resident/fellow interest]
  • Complete list of Medline citations: https://www.ncbi.nlm.nih.gov/sites/myncbi/1bqCzVtcfIPkf/bibliography/41306216/public/?sort=date&direction=ascending
  • POSITIONS:
  • 2012-present Deputy Science Director, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD.
  • 2009-present Director, HIV Research Area, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD.
  • 2005-2008 Deputy Director, HIV Research Area, IDCRP/PMB/USU/HJF and Key Clinical Faculty, Dept. of Iinfectious Diseases, WHMC/San Antonio Military Medical Center, TX.
  • 2001-2005 Director, (Associate Director 2001-03) USAF HIV Unit and Key Clinical Faculty (ID Fellowship Associate Program Director 2003-04), Dept of Infectious Diseases, Wilford Hall Medical Center, Lackland AFB, TX.

Bibliography

  • O'Bryan TA, Agan BK, Tracy RP, Freiberg MS, Okulicz JF, So-Armah K, Ganesan A, Rimland D, Lalani T, Deiss RG, Tramont EC. Racial Comparison of D-dimer Levels in U.S. Male Military Personnel Before and After HIV Infection and Viral Suppression. J Acquir Immune Defic Syndr 2018 Jan 8.
  • Emuren L, Welles S, Evans AA, Polansky M, Okulicz JF, Macalino G, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. Health-related quality of life among military HIV patients on antiretroviral therapy. PLoS One 2017 Jun 7;12(6):e0178953.
  • Crum-Cianflone NF, Won S, Lee R, Lalani T, Ganesan A, Burgess T, Agan BK. Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults. Vaccine 2016 Sep 22;34(41):5040-6.
  • Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O'Bryan T, Rimland D, Justice AC, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLoS One. 2016 Apr 18;11(4):e0152588.
  • Bello KJ, Mesner O, O'Bryan TA, Won SH, Lalani T, Ganesan A, Agan BK, Okulicz JF. Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infect Dis 2016 Jul 22;16:351.
  • Okulicz JF, Le TD, Agan BK, Camargo JF, Landrum ML, Wright E, Dolan MJ, Ganesan A, Ferguson TM, Smith DM, Richman DD, Little SJ, Clark RA, He W, Ahuja SK. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med 2015 Jan;175(1):88-99.
  • Crum-Cianflone NF, Wang X, Ganesan A, Okulicz J, Weintrob A, Lalani T, Agan B. HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. AIDS Res Hum Retroviruses 2015 May;31(5):514-8.
  • Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, Okulicz JF, Bavaro M, Weintrob AC, Justice AC, Agan BK; the Infectious Disease Clinical Research Program HIV Working Group. The VACS Index Predicts Mortality In A Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 2014 Feb 1;65(2):226-30.
  • Crum-Cianflone NF, Moore DJ, Letendre S, Roediger M, Eberly L, Weintrob A, Ganesan A, Johnson E, Del Rosario R, Agan BK, Hale BR. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 80(4): 371-379, 2013 Jan 23.
  • Burt TD*, Agan BK*, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proceedings of the National Academy of Sciences of the United States of America 105(25):8718-23, 2008 Jun 24.